Children account for 7%-20% of cutaneous leishmaniasis cases in Iran, but there are few safety data to guide pediatric antiparasitic therapy. We evaluated the clinical and laboratory tolerance of the systemic pentavalent antimonial compound meglumine antimoniate, in 70 Iranian children with cutaneous leishmaniasis. Adverse effects were similar to those seen in adults.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jpids/piu021 | DOI Listing |
Publication Analysis
Top Keywords
cutaneous leishmaniasis
12
meglumine antimoniate
8
clinical laboratory
8
systemic meglumine
4
antimoniate cutaneous
4
leishmaniasis children
4
children clinical
4
laboratory complications
4
complications children
4
children account
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!